Show simple item record

dc.contributor.authorBonaccorso, Stefania
dc.contributor.authorRicciardi, Angelo
dc.contributor.authorZangani, Caroline
dc.contributor.authorChiappini, Stefania
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2019-12-19T01:06:54Z
dc.date.available2019-12-19T01:06:54Z
dc.date.issued2019-09
dc.identifier.citationBonaccorso , S , Ricciardi , A , Zangani , C , Chiappini , S & Schifano , F 2019 , ' Cannabidiol (CBD) Use in Psychiatric Disorders; A Systematic Review ' , NeuroToxicology , vol. 74 , pp. 282-298 . https://doi.org/10.1016/j.neuro.2019.08.002
dc.identifier.issn0161-813X
dc.identifier.otherPURE: 17184793
dc.identifier.otherPURE UUID: 79b55a74-b9d3-4b4d-9477-e2a132924fbe
dc.identifier.otherScopus: 85071110943
dc.identifier.urihttp://hdl.handle.net/2299/22018
dc.descriptionSubmitted 31 March 2019, Revised version submitted 2 August 2019, Accepted 4 August 2019
dc.description.abstractCannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different activity compared with the psychotomimetic THC. Most typically, CBD is reported to be used in some medical conditions, including chronic pain. Conversely, the main aim of this systematic review is to assess and summarise the available body of evidence relating to both efficacy and safety of CBD as a treatment for psychiatric disorders, alone and/or in combination with other treatments. Eligible studies included randomized controlled trials (RCT) assessing the effect of CBD in a range of psychopathological conditions, such as substance use; psychosis, anxiety, mood disturbances, and other psychiatric (e.g., cognitive impairment; sleep; personality; eating; obsessive-compulsive; post-traumatic stress/PTSD; dissociative; and somatic) disorders. For data gathering purposes, the PRISMA guidelines were followed. The initial search strategy identified some n=1,301 papers; n=190 studies were included after the abstract’s screening and n=27 articles met the inclusion criteria. There is currently limited evidence regarding the safety and efficacy of CBD for the treatment of psychiatric disorders. However, available trials reported potential therapeutic effects for specific psychopathological conditions, such as substance use disorders, chronic psychosis, and anxiety. Further large-scale RCTs are required to better evaluate the efficacy of CBD in both acute and chronic illnesses, special categories, as well as to exclude any possible abuse liability.en
dc.format.extent17
dc.language.isoeng
dc.relation.ispartofNeuroToxicology
dc.subjectCannabidiol (CBD)
dc.subjectPsychiatric Disorders
dc.subjectReview
dc.subjectSubstance use disorders
dc.subjectCBD
dc.subjectMedical marijuana
dc.subjectCannabidiol
dc.subjectPsychiatric disorders
dc.subjectNeuroscience(all)
dc.subjectToxicology
dc.titleCannabidiol (CBD) Use in Psychiatric Disorders; A Systematic Reviewen
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85071110943&partnerID=8YFLogxK
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.neuro.2019.08.002
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record